Nabi Biopharmaceuticals agreed to sell PentaStaph™ (Pentavalent S. aureus vaccine) and related assets to GlaxoSmithKline (GSK) for US$46 M. The vaccine is a potential development in the fight against the multidrug resistant bacterium, S. aureus, and MRSA (methicillin-resistant S. aureus). Troubled Nabi is also on the lookout for a potential acquirer.